Amber Tx logo.png
Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
June 10, 2024 03:00 ET | Amber Therapeutics
US approval would make Amber-UI the first fully implantable adaptive neuromodulation therapy for women with mixed urinary incontinence (MUI)By targeting the pudendal nerve, Amber-UI has the unique...
Amber Theraputics Brand Mark BURNT ORANGE.png
Amber Therapeutics announces positive preliminary results from its first-in-human investigation of Amber-UI, its new adaptive implanted pudendal neuromodulation system for urinary incontinence
February 27, 2024 09:00 ET | Amber Therapeutics
Key initial results from AURA-2 study highlight good safety and scalability of Amber-UI therapy A strong efficacy signal was seen in the form of complete resolution of incontinence episodes six months...
Amber Theraputics Brand Mark BURNT ORANGE.png
Amber Tx acquires Bioinduction Limited and its Picostim DyNeuMo platform, on which Amber’s closed-loop neuromodulation therapy for mixed urinary incontinence is being developed
September 05, 2023 03:00 ET | Amber Therapeutics
Acquisition of Bioinduction transforms Amber into an integrated developer and manufacturer of intelligent, closed-loop neuromodulation therapies.Amber-UI therapy for mixed incontinence is currently...